Advances in Gene Therapy: Harnessing the Power of CRISPR/Cas9 for Precision Medicine
DOI:
https://doi.org/10.36676/ssjmra.v1.i3.22Keywords:
Gene therapy, CRISPR/Cas9, Precision medicine, Genetic disorders, Genome editingAbstract
Gene therapy has emerged as a revolutionary approach for treating genetic disorders by introducing, removing, or modifying genes within an individual's cells. The development of CRISPR/Cas9 technology has revolutionized the field of gene therapy, offering a precise and efficient tool for editing the human genome. This abstract explores recent advances in gene therapy, focusing on the application of CRISPR/Cas9 technology for precision medicine. By harnessing the power of CRISPR/Cas9, researchers can target specific genes associated with genetic diseases, enabling precise correction of disease-causing mutations. This review discusses the potential of CRISPR/Cas9-based gene therapy for treating a wide range of genetic disorders, including inherited monogenic diseases, cancer, and infectious diseases. Additionally, it highlights the challenges and ethical considerations associated with CRISPR/Cas9-mediated genome editing and explores future directions for advancing gene therapy towards clinical translation. Overall, CRISPR/Cas9 technology holds tremendous promise for revolutionizing the field of precision medicine and improving outcomes for patients with genetic disorders.
References
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
Gaj, T., Gersbach, C. A., & Barbas III, C. F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology, 31(7), 397-405.
Goyal, A. (2024). Advancements in Gene Therapy for Rare Genetic Disorders. Shodh Sagar Journal for Medical Research Advancement, 1(1), 10–18. https://doi.org/10.36676/ssjmra.v1.i1.02
Hiya Kachhawa. (2022). Gene therapy in diabetes: A review of case study conducted over mice to cure type 2 diabetes and obesity. International Journal for Research Publication and Seminar, 13(2), 163–170. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/586
Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6), 1262-1278.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.
Kiani, S., Chavez, A., Tuttle, M., Hall, R. N., Chari, R., Ter-Ovanesyan, D., ... & Church, G. M. (2015). Cas9 gRNA engineering for genome editing, activation and repression. Nature Methods, 12(11), 1051-1054.
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., ... & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823-826.
Manpreet. (2015). Gene therapy in diabetes: A review of case study conducted over mice to cure type 2 diabetes and obesity. International Journal for Research Publication and Seminar, 6(1), 140–146. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/53
Sander, J. D., & Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology, 32(4), 347-355.
Singh, S. (2024). Gene Editing Technologies: CRISPR/Cas9 and Beyond for Genetic Disease Therapy and Research. Universal Research Reports, 11(3), 1–7. https://doi.org/10.36676/urr.v11.i3.1280
Wang, H., La Russa, M., & Qi, L. S. (2016). CRISPR/Cas9 in genome editing and beyond. Annual Review of Biochemistry, 85, 227-264.
Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016). Biology and applications of CRISPR systems: harnessing nature’s toolbox for genome engineering. Cell, 164(1-2), 29-44.
Zhang, F., Wen, Y., & Guo, X. (2014). CRISPR/Cas9 for genome editing: progress, implications and challenges. Human Molecular Genetics, 23(R1), R40-R46.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Shodh Sagar Journal for Medical Research Advancement
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.